Month: July 2018

Biosimilars Pharma

Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar

Shots: Trazimera is a biosimilar of Herceptin indicated for treatment of HER2 overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma The EC approval is based on the data including REFLECTION B327-02 clinical study showing similarity b/w Trazimera and original product in patient Trazimera has been studied in ~500 patients across 20 countries Click […]Read More


Pernix Therapeutics Buys Orexigen’s Contrave for $73.5Mn

Shots:  Nalpropion buys global commercialization rights of Orexigen’s Contrave a weight loss drug. Nalpropion is an investor group which includes Pernix  Contrave has approx. 2.5 Mn prescription since 2014, presently, it is launched in 25 countries with expected launch in 13 countries in 2018 and has an US exclusivity till 2030 Pernix will have an […]Read More


Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine

Shots:   Results of 2600 patients trial reported significant i.e. ≥50% reduction in migraine days with comparable safety and tolerability to PBO   Aimovig works by blocking calcitonin gene-related peptide receptor (CGRP-R) which plays vital role in migraine   Can be self-administered every four weeks with the Sure Click®️ auto injector pen, device commonly used for […]Read More


BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology

Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study  Results of Ph2a COMBAT study is expected in H2’18 as planned This study is assessing combination of BL-8040 & Keytruda in metastatic 1L+ patients Click here to read full press release/ article | Ref: Biolinerx […]Read More


Lilly Announces an Extension to 2015 Research Collaboration deal with

Shots: The extension provides a better understanding to clinicians and initial funding discoveries, molecular analyses, design and conduct of samples for new discoveries in cancer Agreement defines that Dana has right to perform multiple clinical and preclinical trials adding in Lilly’s pipeline Evaluated compound ownership will remain under Lilly Click here to read full press […]Read More